Perspective Therapeutics CATX
Perspective Therapeutics, Inc. · NYSE · Pharmaceutical Preparations
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 4, 2026 | Lantheus Alpha Therapy LLC with Lantheus Holdings Inc. 10% owner | Sold | 167,149 | $3.15 | $526,051 |
| Sept. 3, 2026 | Lantheus Alpha Therapy LLC with Lantheus Holdings Inc. 10% owner | Sold | 80,783 | $3.11 | $250,896 |
| Sept. 2, 2026 | Lantheus Alpha Therapy LLC with Lantheus Holdings Inc. 10% owner | Sold | 42,129 | $3.11 | $131,219 |
| Sept. 1, 2026 | Lantheus Alpha Therapy LLC 10% owner | Sold | 35,769 | $3.12 | $111,574 |
| Sept. 1, 2026 | Lantheus Holdings Inc. 10% owner | Sold | 35,769 | $3.12 | $111,574 |
| Aug. 31, 2026 | Lantheus Alpha Therapy LLC 10% owner | Sold | 78,145 | $3.14 | $245,610 |
| Aug. 31, 2026 | Lantheus Holdings Inc. 10% owner | Sold | 78,145 | $3.14 | $245,610 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 18 →Other events · Financial statements and exhibits
AI summary, unreviewedPerspective Therapeutics Reports Updated Phase 1/2a VMT-α-NET Data at ESMO: 50% ORR in 6.0 mCi Cohort, 72% PFS at 18 Months
Other events · Financial statements and exhibits
AI summary, unreviewedPerspective Therapeutics Granted FDA Fast Track Designation for PSV359 in FAP-Positive Solitary Fibrous Tumors
Other events · Financial statements and exhibits
AI summary, unreviewedPerspective Therapeutics Updates Corporate Presentation With Pipeline Data for VMT-α-NET, VMT01 and PSV359, No Financial Results Disclosed
Other events · Financial statements and exhibits
Other events · Financial statements and exhibits